Direct effects of poly(epsilon-caprolactone) lipid-core nanocapsules on human immune cells

Autor(es):Mostrar menos -

Sandri, Silvana ^[1] ; Hebeda, Cristina Bichels ^[1] ; Loiola, Rodrigo Azevedo ^[1] ; Calgaroto, Selma ^[2] ; Uchiyama, Mayara Klimuk ^[3] ; Araki, Koiti ^[3] ; Frank, Luiza Abrahao ^[4] ; Paese, Karina ^{[4, 2]} ; Guterres, Silvia Staniscuaski ^[4] ; Pohlmann, Adriana Raffin ^{[4, 2]} ; Poliselli Farsky, Sandra Helena ^[1]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Sch Pharmaceut Sci, Dept Clin & Toxicol Anal, Sao Paulo - Brazil

^[2] Univ Fed Rio Grande do Sul, Dept Organ Chem, Postgrad Program Chem, Inst Chem, Porto Alegre, RS - Brazil

^[3] Univ Sao Paulo, Dept Fundamental Chem, Inst Chem, Sao Paulo - Brazil

^[4] Univ Fed Rio Grande do Sul, Dept Prod & Control Pharmaceut, Postgrad Program Pharmaceut Sci, Fac Pharmaceut Sci, Porto Alegre, RS - Brazil

• Tipo de documento: Artigo Científico
• Fonte: Nanomedicine; v. 14, n. 11, p. 1429-1442, JUN 2019.
• Citações Web of Science: 1

Resumo

Aim: Poly(epsilon-caprolactone) lipid-core nanocapsules (LNCs) are efficient drug carriers and drug-free LNCs display therapeutic effects, inhibiting tumor growth and neutrophil activities. Herein, we investigated the direct actions of LNCs on human immune cells, to guide their therapeutic application. Materials \& methods: LNC's uptake, cytokine release, cell migration, proliferation and intracellular pathways under inflammatory stimulation were investigated. Results \& conclusion: LNCs quickly penetrated leukocytes without cytotoxicity; inhibited mitogen-induced lymphocyte proliferation, cytokine release and leukocyte migration under inflammatory stimulation, which were associated with inhibition of the MAP kinase pathway and intracellular calcium influx. Hence, we showed LNCs as a down-regulatory agent on immune cells, suggesting that either the particles themselves or their application as a drug carrier can halt non-desired inflammatory processes. (AU)

• Processo FAPESP: 14/07328-4 - Identificação de vias endógenas para o controle da inflamação
• Beneficiário: Sandra Helena Poliselli Farsky
• Modalidade de apoio: Auxílio à Pesquisa - Temático